AlbiglutideHistorical GLP-1 receptor agonist
Albiglutide is a long-acting GLP-1 receptor agonist developed for type 2 diabetes. Its clinical results need to be considered separately from its current availability.
What is Albiglutide?
Albiglutide is a long-acting GLP-1 receptor agonist developed as a treatment for type 2 diabetes. It combines GLP-1-related activity with an albumin-based structure.
How it works
Activation of GLP-1 receptors influences glucose-dependent insulin secretion and meal-related glucose control. The albumin-based structure prolongs exposure.
Effects studied
Blood glucose and cardiovascular outcomes
The diabetes programme included glucose-control studies and HARMONY Outcomes, which studied cardiovascular events in people with type 2 diabetes and cardiovascular disease. These are separate outcomes; historical evidence does not establish current product availability.
Evidence: Diabetes trials; cardiovascular-outcome trial retained for review
What does the evidence show?
Diabetes and cardiovascular-outcome trial history
Extending a peptide’s time in the body
Albiglutide links GLP-1-related activity with an albumin-based structure to prolong exposure. The receptor pathway influences glucose-dependent insulin secretion and other meal-related processes. It belongs to the development history of longer-acting diabetes medicines rather than to a general supplement category.
What the studies contributed
The retained HARMONY Outcomes reference concerns cardiovascular outcomes in people with type 2 diabetes and cardiovascular disease. Cardiovascular events are a different outcome from a lower HbA1c. A molecule can therefore remain scientifically informative even when it is no longer widely supplied.
What happened to the European product
The EMA states that Eperzan’s marketing authorisation was withdrawn in October 2018 at the company’s request, following a decision to discontinue marketing for commercial reasons. That statement should not be rewritten as proof that the medicine was withdrawn because it was ineffective or unsafe. 1
Evidence and availability need separate labels
An old positive study is not a prescription recommendation for a product that may no longer be available. Equally, withdrawal does not make every trial result irrelevant. The study population, clinical outcomes and product history remain useful for understanding this medicine. They do not establish that albiglutide is a current routine option in Germany or Switzerland.
Safety & status
The EU withdrawal notice gives commercial reasons, not a finding of ineffectiveness or a new safety verdict. It is not a full adverse-effect assessment. 1
Country and product status
EMA confirms withdrawal of Eperzan’s EU authorisation in October 2018 at the manufacturer’s request for commercial reasons.
Frequently asked questions
Is Eperzan still authorised in the EU?
EMA records withdrawal of its authorisation in October 2018 at the manufacturer’s request for commercial reasons. 1
Was it withdrawn because it did not work?
That is not the reason given by EMA. Commercial discontinuation and the interpretation of clinical trial results are separate questions. 1
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- EMA · Eperzan withdrawal public statement European regulator · Regulator information checked 27 October 2026; indication-specific, not a review of all jurisdictions.
- Albiglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Albiglutide · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.